Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 25,224 |
|
|||||
| News | (1) | ||||||
| Day High | 8.75 | Low High |
|||||
| Day Low | 8.40 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Coya Therapeutics Inc | COYA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.17 | 2.02% | 8.60 | 17:16:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.55 | 8.40 | 8.75 | 8.60 | 8.43 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 286 | 25,224 | $ 8.54 | $ 215,369 | - | 3.21 - 10.6899 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:35:01 | 10 | $ 8.17 | USD |
Coya Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 85.66M | 10.03M | - | 6M | -7.99M | -0.80 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Coya Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COYA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.43 | 9.22 | 7.81 | 8.27 | 63,643 | 0.17 | 2.02% |
| 1 Month | 9.97 | 10.23 | 7.81 | 8.91 | 59,182 | -1.37 | -13.74% |
| 3 Months | 6.20 | 10.6899 | 5.83 | 9.06 | 103,814 | 2.40 | 38.71% |
| 6 Months | 4.77 | 10.6899 | 4.40 | 8.13 | 73,555 | 3.83 | 80.29% |
| 1 Year | 4.73 | 10.6899 | 3.21 | 6.32 | 86,234 | 3.87 | 81.82% |
| 3 Years | 4.75 | 10.6899 | 3.21 | 6.18 | 70,677 | 3.85 | 81.05% |
| 5 Years | 4.75 | 10.6899 | 3.21 | 6.18 | 70,677 | 3.85 | 81.05% |
Coya Therapeutics Description
| Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. |
